RVT-2301-201 - A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Pulmovant, Inc.
Start Date
October 24, 2024
End Date
September 14, 2029
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Pulmovant, Inc.
Start Date
October 24, 2024
End Date
September 14, 2029